Streetbeat News

Earnings

ATXI

Avenue Therapeutics (NASDAQ:ATXI) reported a Q4 EPS loss of $(0.98), missing the consensus estimate of $(0.10) by 880%, but marking a 20.33% improvement over last year's $(1.23) loss per share.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:15 pm

FBRX

Forte Biosciences, Inc. reported an increase in its 2023 EPS loss to $(1.00) from $(0.80) YoY. R&D expenses rose to $21.9 million, driven by manufacturing, preclinical, and clinical expenses, notably for the FB-102 program. G&A expenses also increased to $10.6 million due to higher professional and legal costs. The company ended the year with $37.1 million in cash and 36.3 million shares outstanding.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:13 pm

PBM

Psyence Biomedical Ltd. (NASDAQ:PBM) welcomed a study published in Molecular Psychiatry, showing nature-derived psilocybin may be more therapeutic than synthetic versions, particularly in neuroplasticity effects. The study, not funded by Psyence Biomed, was conducted by Hebrew University. Psyence Biomed, focusing on nature-derived psilocybin for Palliative Care, is preparing for a Phase llb clinical trial targeting Adjustment Disorder in cancer patients. The U.S. Palliative Care market is expected to grow to $28.6 billion by 2030. Psyence Biomed's approach could potentially improve patient quality of life and reduce healthcare costs.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:11 pm

AUGX

Augmedix (NASDAQ:AUGX) reported Q4 earnings, beating estimated earnings by 10.0% with an EPS of $-0.09 versus an estimate of $-0.1. Revenue increased by $3.93 million from the same period last year. The company's past performance shows a consistent beat on EPS estimates, leading to a 13.0% share price increase the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 8:10 pm

RCAT

Red Cat Holdings (NASDAQ:RCAT) reported Q3 earnings with an EPS of $-0.08, missing estimates by -100% against an expected $-0.04. Revenue increased by $2.74 million year-over-year. Despite past earnings misses, the company's share price increased by 9.0% the day after last quarter's earnings were announced.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 8:10 pm

ADVM

Adverum Biotechnologies reported a Q4 EPS loss of $0.23, surpassing the analyst consensus estimate of a $0.34 loss by 32.35%. This represents a 30.3% improvement over the $0.33 loss per share from the same period last year.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:09 pm

TNYA

Tenaya Therapeutics (NASDAQ:TNYA) reported Q4 earnings with losses of $(0.40) per share, surpassing the analyst consensus estimate of $(0.44) by 9.09%. This represents a 34.43% improvement over the previous year's losses of $(0.61) per share.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:09 pm

MOTS

Motus GI Holdings (MOTS) reported Q4 earnings with a loss of $4.48 per share, missing the consensus estimate of $4.39, and sales of $64K, also missing the estimate of $150K. This represents a 62.19% improvement in losses and a 41.28% decrease in sales year-over-year.

Portfolio Pulse from Happy Mohamed

March 18, 2024 | 8:08 pm

REYN

Reynolds Consumer Products has reaffirmed its financial guidance for both Q1 2024 and the full year of 2024. Additionally, the company has introduced its vision for the year 2030, outlining its long-term strategic goals.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:06 pm

AUGX

Augmedix reported Q4 2023 earnings with a GAAP EPS of $(0.09), surpassing the $(0.10) estimate. Sales reached $12.680M, exceeding the $12.466M forecast and marking a 44.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 18, 2024 | 8:05 pm